Citigroup’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

Citigroup’s Portfolio BSX.PRA Stock Details BSX.PRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-47,500	Closed	-$5.75M	–	5852
2023 Q1	$5.75M	Buy	47,500 +29,447	+163%	+$3.39M	﹤0.01%	1431
2022 Q4	$2.07M	Buy	+18,053	New	+$1.99M	﹤0.01%	2009
2020 Q4	–	Sell	-200	Closed	-$22K	–	7700
2020 Q3	$22K	Buy	+200	New	+$22.4K	﹤0.01%	6148

Other funds holding BSX.PRA

LTI

Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Citigroup's BSX.PRA Position: Q2 2023 in Review

Citigroup sold out of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) in Q2 2023, closing a stake of 47,500 shares — an estimated $5.75M sold.

Citigroup first reported a position in BSX.PRA in Q3 2020 and held it in 3 quarters. The position peaked at $5.75M in Q1 2023. 1 fund tracked by Wall St. Rank holds BSX.PRA as of Q2 2023.

Citigroup reported no remaining Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position as of Q2 2023 after selling out during the quarter.
Citigroup sold 47,500 Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A shares in Q2 2023, an estimated $5.75M.
Citigroup first reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q3 2020 and held it in 3 quarters.
Citigroup's Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position peaked at $5.75M in Q1 2023.
1 fund tracked by Wall St. Rank held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A as of Q2 2023.

Based on Citigroup's 13F filing for Q2 2023, filed 10 Aug 2023.